Compare ARK Genomic Revolution ETF (ARKG) vs Bath & Body Works Inc (BBWI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Bath & Body Works Inc — how do they compare? ARK Genomic Revolution ETF trades at $40.95, while Bath & Body Works Inc trades at $20.33 (market cap $4.10B). The key difference: Bath & Body Works Inc pays a 3.94% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Bath & Body Works Inc nearer its low. Which is the better fit depends on your goals.
| ARKG | BBWI | |
|---|---|---|
Sector | Sector/Thematic | Consumer Cyclical |
52-Week High | $43.57 | $33.11 |
52-Week Low | $23.09 | $14.85 |
Market Cap | — | $4.10B |
Enterprise Value | — | $7.99B |
Dividend Yield | — | 3.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
BBWI trades at $20.33, up 2.01% today, with a bearish technical signal but neutral oscillators. The stock shows strong profitability with a net margin of 10.03% and attractive valuation ratios, including a P/E of 5.78. Recent earnings beat expectations in Q1 2026, and the company's partnership with Ulta Beauty aims to expand reach. Cash flow trends indicate improving net cash flow by 2026, though the balance sheet carries significant debt.
The outlook is mixed: analyst consensus is a Buy with a $22.00 price target, suggesting upside, but risks include declining revenue over five years and high leverage. The Ulta partnership and cost-saving initiatives offer growth potential, yet competitive pressures and macroeconomic headwinds pose challenges for sustained performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Bath & Body Works Inc
Bath & Body Works is a specialty home fragrance and fragrant body care retailer operating under the Bath & Body Works, C.O. Bigelow, and White Barn brands. The company generates most of its business in North America, with less than 5% of sales from international markets in fiscal 2021. For fiscal 2021, 72% of sales stemmed from the brick-and-mortar network (which is composed of more than 1,700 retail stores), up from 65% in 2020, as consumer shopping patterns began to return to normal. Future growth is expected from store reformatting, digital and international channels, as well as new category expansion.
Read more on BBWI →
